BioLife Solutions (FRA:BJX1) Cyclically Adjusted FCF per Share: €-0.09 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BJX1 BioLife Solutions Inc FRA:BJX1
73 GF Score
Price €30.40
GF Value €26.03
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is BioLife Solutions Cyclically Adjusted FCF per Share?

BioLife Solutions FRA:BJX1 +0.66% 73 Cyclically Adjusted FCF per Share is €-0.09 as of Jun. 2026. GuruFocus rates FRA:BJX1 with a GF Score™ of 73/100 and a GF Value™ of €26.03 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioLife Solutions's adjusted free cash flow per share for the three months ended in Jun. 2026 was €0.091. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.09 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 14.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioLife Solutions was 37.00% per year. The lowest was -21.60% per year. And the median was 8.00% per year.

As of today (2026-08-17), BioLife Solutions's current stock price is €30.40. BioLife Solutions's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.09. BioLife Solutions's Cyclically Adjusted Price-to-FCF of today is .


BioLife Solutions  (FRA:BJX1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioLife Solutions Cyclically Adjusted FCF per Share Related Terms


BioLife Solutions Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Cyclically Adjusted FCF per Share Chart

BioLife Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -0.20 -0.25 -0.20 -0.12

BioLife Solutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.11 -0.12 -0.10 -0.09

FRA:BJX1 vs AZTA, KMTS, STAA: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Cyclically Adjusted Price-to-FCF falls into.


FRA:BJX1
73GF Score
BioLife Solutions Inc FRA:BJX1
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLife Solutions Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLife Solutions's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.091/333.9520*333.9520
=0.091

Current CPI (Jun. 2026) = 333.9520.

BioLife Solutions Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.076 241.428 -0.105
201612 -0.069 241.432 -0.095
201703 -0.015 243.801 -0.021
201706 -0.010 244.955 -0.014
201709 0.004 246.819 0.005
201712 0.046 246.524 0.062
201803 0.020 249.554 0.027
201806 0.023 251.989 0.030
201809 0.019 252.439 0.025
201812 0.020 251.233 0.027
201903 0.054 254.202 0.071
201906 -0.002 256.143 -0.003
201909 0.041 256.759 0.053
201912 -0.044 256.974 -0.057
202003 0.023 258.115 0.030
202006 0.156 257.797 0.202
202009 -0.017 260.280 -0.022
202012 -0.050 260.474 -0.064
202103 -0.014 264.877 -0.018
202106 -0.200 271.696 -0.246
202109 -0.006 274.310 -0.007
202112 -0.036 278.802 -0.043
202203 -0.203 287.504 -0.236
202206 -0.266 296.311 -0.300
202209 -0.022 296.808 -0.025
202212 0.071 296.797 0.080
202303 -0.130 301.836 -0.144
202306 -0.177 305.109 -0.194
202309 -0.126 307.789 -0.137
202312 0.027 306.746 0.029
202403 -0.098 312.332 -0.105
202406 0.110 314.175 0.117
202409 0.072 315.301 0.076
202412 0.012 315.605 0.013
202503 0.030 319.799 0.031
202506 0.102 322.561 0.106
202509 0.049 324.800 0.050
202512 -0.158 324.054 -0.163
202603 -0.012 330.213 -0.012
202606 0.091 333.952 0.091

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.09 mean?
BioLife Solutions (FRA:BJX1) has a Cyclically Adjusted FCF per Share of €-0.09 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioLife Solutions and its competitors.
Is BioLife Solutions' Cyclically Adjusted FCF per Share too high?
BioLife Solutions' current Cyclically Adjusted FCF per Share is €-0.09. Overall, BioLife Solutions has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Cyclically Adjusted FCF per Share compare to AZTA and KMTS?
BioLife Solutions' Cyclically Adjusted FCF per Share of €-0.09 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioLife Solutions and its competitors. BioLife Solutions's current Cyclically Adjusted FCF per Share is €-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (FRA:BJX1) is currently considered Modestly Overvalued. The stock's GF Value™ is €26.03, compared to a current price of €30.40 — trading 16.8% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.09. BioLife Solutions' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioLife Solutions (FRA:BJX1), the current Cyclically Adjusted FCF per Share is €-0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (FRA:BJX1) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of €30.40 is trading 16.8% above its estimated GF Value™ of €26.03. GuruFocus considers BioLife Solutions to be Modestly Overvalued.

Key valuation signals for FRA:BJX1:

  • Cyclically Adjusted FCF per Share: €-0.09
  • GF Value™: €26.03 vs. price of €30.40 (16.8% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the FRA:BJX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioLife Solutions Business Description

Other Exchanges BLFS:USA
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
73GF Score

Get the complete analysis for FRA:BJX1

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.40
Price
€26.03
GF Value